UK cost watchdog says no to Novartis MS pill | Reuters

Links shared publicly online about this topic.

  • 94
    total visits

UK cost watchdog says no to Novartis MS pill | Reuters

reuters.com

LONDON (Reuters) - Novartis's multiple sclerosis pill Gilenya, one of its biggest new drug hopes, has been rejected by Britain's healthcare cost-effectiveness watchdog NICE, which judges it not worth using

View full resource at reuters.com

Tags: Multiple Sclerosis, Drug, Healthcare, Novartis

  • Share

Most Recently Shared on August 5, 2011 at 6:56 pm By:

MedicalNews Medical News

UK cost watchdog says no to Novartis MS pill http://bit.ly/p4OMjr

10 months ago...

UK cost watchdog says no to Novartis MS pill - Yahoo! News

news.yahoo.com — “Read 'UK cost watchdog says no to Novartis MS pill' on Yahoo! News. LONDON (Reuters) - Novartis's multiple sclerosis pill Gilenya, one of its biggest new drug hopes, has been rejected by Britain's healthcare cost-effectiveness watchdog NICE, which judges it not worth using on the state health service.View full resource at news.yahoo.com

  • View Related
  • Share

Most Recently Shared on August 5, 2011 at 8:49 pm By:

MS_Wisdom2 OrganizedWisdom MS OW Health

UK cost watchdog says no to Novartis MS pill: LONDON (Reuters) - Novartis's multiple sclerosis pill Gilenya, on... http://yhoo.it/nCekpL

10 months ago...

UK cost watchdog says no to Novartis MS pill | Reuters

reuters.com — “LONDON (Reuters) - Novartis's multiple sclerosis pill Gilenya, one of its biggest new drug hopes, has been rejected by Britain's healthcare cost-effectiveness watchdog NICE, which judges it not worth usingView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on August 5, 2011 at 6:42 pm By:

Advertisement